Soligenix Inc (SNGX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christopher J. Schaber
Employees:
14
29 EMMONS DRIVE, SUITE C-10, PRINCETON, NJ 08540
609-538-8200

Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments. The BioTherapeutics segment involves in the development of photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. The Vaccines or BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.

Data derived from most recent annual or quarterly report
Market Cap 15.961 Million Shares Outstanding40.104 Million Avg 30-day Volume 158.355 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.11
Price to Revenue32.1489 Debt to Equity0.9192 EBITDA-12.652 Million
Price to Book Value2.4713 Operating Margin-1594.2491 Enterprise Value10.312 Million
Current Ratio4.223 EPS Growth0.516 Quick Ratio4.156
1 Yr BETA 0.4207 52-week High/Low 1.34 / 0.38 Profit Margin-1522.6811
Operating Cash Flow Growth-2.4898 Altman Z-Score-10.3632 Free Cash Flow to Firm -8.274 Million
Earnings Report2022-05-16
View SEC Filings from SNGX instead.

View recent insider trading info

Funds Holding SNGX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SNGX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT

47,315 2022-01-21 4

GUARINO JONATHAN L. CHIEF FINANCIAL OFFICER

50,000 2022-01-21 4

STRAUBE RICHARD CMO

  • Officer
40,000 2021-12-09 1

DONINI OREOLA CSO

  • Officer
70,000 2021-12-09 1

LAPOINTE ANTHONY GREGG

  • Director
29,126 2021-09-23 1

RUBIN ROBERT J.

  • Director
29,126 2021-09-23 1

ZELDIS JEROME B

  • Director
29,126 2021-09-23 1

PARKS DIANE L.

  • Director
29,126 2021-09-23 1

PEARSON MARK E.

  • Director
  • 10% Owner
0 2019-09-06 0

KRUMEICH KAREN R SVP AND CFO

  • Officer
0 2018-12-13 0

BROWNLIE KEITH L

  • Director
0 2018-09-27 0

ESSETIFIN SPA

CAVAZZA PAOLO

LEADIANT BIOSCIENCES, INC.

CAVAZZA ENRICO

CAVAZZA FRANCESCA

CAVAZZA SILVIA

CAVAZZA PRETA MARTINA

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2017-11-29 0

BRUGHERA MARCO MARIA

  • Director
0 2017-06-08 0

KIRK RANDAL J

INTREXON CORP

  • 10% Owner
No longer subject to file 2017-05-04 0

WARUSZ JOSEPH MICHAEL VP OF FINANCE/ACTING CFO

  • Officer
0 2015-12-31 0

BREY ROBERT N CHIEF SCIENTIFIC OFF., SR. VP

  • Officer
0 2013-12-05 0

HORGAN KEVIN CHIEF MEDICAL OFFICER & SR. VP

  • Officer
0 2013-09-25 0

SIGMA TAU FINANZIARIA SPA

SIGMA TAU INTERNATIONAL SA

SIGMA-TAU AMERICA S.A.

SIGMA-TAU PHARMACEUTICALS, INC.

  • 10% Owner
2,711,392 2012-12-20 0

CAVAZZA PAOLO

  • 10% Owner
2,935,077 2012-12-20 0

MYRIANTHOPOULOS EVAN SR VP AND CFO

  • Officer
  • Director
0 2011-12-01 0

HOWSON TAMAR D

  • Director
0 2011-06-22 0

THOMPSON VIRGIL

  • Director
0 2011-06-22 0

SCHNITTKER CHRISTOPHER P. VP-ADMIN., CONTROLLER

  • Officer
0 2010-09-23 0

HAMILTON BRIAN L CHIEF MEDICAL OFFICER & SR VP

  • Officer
0 2010-09-23 0

BAM MANAGEMENT LLC

BERMAN ROSS

MINTZ HAL

  • 10% Owner
No longer subject to file 2010-08-18 0

CAVAZZA CLAUDIO

  • 10% Owner
54,227,817 2010-06-18 0

BIOTEX PHARMA INVESTMENTS, LLC

  • 10% Owner
17,665,000 2009-10-09 0

KUO JAMES S

  • Director
0 2009-06-04 0

BUHRMAN CYRILLE F

  • Director
4,900,020 2009-06-04 0

CLAVIJO JAMES CONTROLLER/TREASURER

  • Officer
0 2008-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SOLIGENIX INC SNGX 2022-05-16 16:45:03 UTC -6.4548 7.2748 700000
SOLIGENIX INC SNGX 2022-05-16 16:15:03 UTC -6.4548 7.2748 750000
SOLIGENIX INC SNGX 2022-05-16 15:45:03 UTC -6.4548 7.2748 750000
SOLIGENIX INC SNGX 2022-05-16 15:15:03 UTC -6.4548 7.2748 750000
SOLIGENIX INC SNGX 2022-05-16 14:45:03 UTC -6.855 7.675 750000
SOLIGENIX INC SNGX 2022-05-16 14:15:03 UTC -6.855 7.675 750000
SOLIGENIX INC SNGX 2022-05-16 13:45:04 UTC -6.855 7.675 750000
SOLIGENIX INC SNGX 2022-05-16 13:15:03 UTC -6.855 7.675 750000
SOLIGENIX INC SNGX 2022-05-16 12:45:04 UTC -6.855 7.675 750000
SOLIGENIX INC SNGX 2022-05-13 22:15:03 UTC -6.855 7.675 500000
SOLIGENIX INC SNGX 2022-05-13 21:45:03 UTC -6.8763 7.6963 500000
SOLIGENIX INC SNGX 2022-05-13 21:15:03 UTC -6.8763 7.6963 500000
SOLIGENIX INC SNGX 2022-05-13 20:45:03 UTC -6.9028 7.7228 500000
SOLIGENIX INC SNGX 2022-05-13 20:15:03 UTC -6.9028 7.7228 500000
SOLIGENIX INC SNGX 2022-05-13 19:45:04 UTC -6.9028 7.7228 500000
SOLIGENIX INC SNGX 2022-05-13 19:15:03 UTC -6.9028 7.7228 500000
SOLIGENIX INC SNGX 2022-05-13 18:45:03 UTC -6.7683 7.5883 500000
SOLIGENIX INC SNGX 2022-05-13 18:15:03 UTC -6.7683 7.5883 500000
SOLIGENIX INC SNGX 2022-05-13 17:45:03 UTC -6.7683 7.5883 500000
SOLIGENIX INC SNGX 2022-05-13 17:15:03 UTC -6.7683 7.5883 500000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund SNGX -9200.0 shares, $-6074.76 2021-12-31 N-PORT

Elevate your investments